"10.1371_journal.pone.0147635","plos one","2016-01-25T00:00:00Z","Sadanori Okada; Takeshi Morimoto; Hisao Ogawa; Mio Sakuma; Hirofumi Soejima; Masafumi Nakayama; Hideaki Jinnouchi; Masako Waki; Yasuhiro Akai; Hitoshi Ishii; Yoshihiko Saito; investigators for the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) trial","Department of Diabetology, Nara Medical University, Kashihara, Nara, Japan; First Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan; Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Department of Cardiovascular Medicine, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan; Diabetes Care Center, Jinnouchi Hospital, Kumamoto, Japan; Division of Endocrinology and Metabolism, Department of Internal Medicine, Shizuoka City Hospital, Shizuoka, Japan; Department of Regulatory Medicine of Blood Pressure, Nara Medical University, Kashihara, Nara, Japan","Conceived and designed the experiments: SO TM HO MS HS MN YS. Analyzed the data: SO TM YS. Contributed reagents/materials/analysis tools: SO HO HS HJ MW YA HI YS. Wrote the paper: SO TM YS.","Dr. TM reports receiving research grants from Bayer HealthCare and lecturers fees from Daiichi-Sankyo, Eisai, Kowa Pharmaceutical, Kyorin Pharmaceutical, and Pfizer Japan for the past three years. Dr. HO reports receiving research grants from AstraZeneca Pharmaceutical, Astellas Pharma, Bayer HealthCare, Boehringer Ingelheim Pharmaceutical, Bristol-Myers, Chugai Pharmaceutical, Daiichi Sankyo, Sumitomo Dainippon Pharma, Kowa Pharmaceutical, MSD, Novartis, Otsuka Pharmaceutical, Pfizer Japan, Sanofi, and Takeda Pharmaceutical and lecturers fees from AstraZeneca Pharmaceutical, Bayer HealthCare, Daiichi-Sankyo, MSD, Pfizer Japan, Sanofi, and Taisho Pharmaceutical for the past three years. Dr. HI reports receiving research grant support from Novo Nordisk and Mitsubishi Tanabe Pharma and lecturers fees from AstraZeneca Pharmaceutical, Eli Lilly Japan, Sanofi, Daiichi Sankyo, Sumitomo Dainippon Pharma, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, Novartis Pharma, Novo Nordisk, Boehringer Ingelheim Pharmaceutical, and MSD. Dr. YS reports receiving research grant support from Ono Pharmaceutical, MSD, Mitsubishi Tanabe Pharma, Daiichi Sankyo, Takeda Pharmaceutical, Novartis Pharma, Shionogi, Astellas Pharma, Otsuka Pharmaceutical, St. Jude Medical Japan, and Kyowa Hakko Kirin; lecturers fees from MSD, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical, Daiichi Sankyo, Otsuka Pharmaceutical, and Pfizer Japan; and consulting fees from Ono Pharmaceutical for the past three years. The rest of the authors have declared that no competing interests exist. Our competing interests do not alter our adherence to PLOS ONE policies on sharing data and materials","2016","01","Sadanori Okada","SO",12,FALSE,7,NA,3,3,TRUE,TRUE,TRUE,1,"12",TRUE
